Cellmid, Fujikura Kasei Co. Ltd. deal

Cellmid said Fujikura exercised its option to license use of Cellmid's midkine ( MDK; MK) diagnostic antibodies on Fujikura's latex-based assay technology. Fujikura paid a ¥40 million ($398,800) fee....